[Skip to Content]
[Skip to Content Landing]
JAMA Dermatology Clinical Evidence Synopsis
May 2017

Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review

Author Affiliations
  • 1Department of Dermatology & Academic Wound Healing, Institute of Infection & Immunity, Cardiff University, Wales
JAMA Dermatol. 2017;153(5):458-459. doi:10.1001/jamadermatol.2017.0432
Abstract

Clinical Question  Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults?

Bottom Line  There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, −3.7 to −2.0 points) and 1.6 points (95% CI, −3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.

×